MEN‐1

:   multiple endocrine neoplasia type 1

SNV

:   single nucleotide variant

Insulinoma is a rare and sporadically occurring neuroendocrine tumor that secretes an excess of insulin, resulting in symptoms of hypoglycemia in patients [1](#feb412366-bib-0001){ref-type="ref"}. Additionally, the catecholamines released from insulinoma produce several symptoms including sweating, nausea, weakness, anxiety and palpitation [2](#feb412366-bib-0002){ref-type="ref"}. Insulinoma is usually a benign neoplasm that is smaller than 2 cm in diameter, without signs of angiogenesis or metastases, and is easily curable by surgical resection [2](#feb412366-bib-0002){ref-type="ref"}. However, an understanding of the mechanism of the pathology of insulinoma is still needed. The small number of disease cases and lack of suitable animal models and cell strains have limited the study of the pathogenesis of insulinoma. The risk factors and related molecular mechanisms of insulinoma remain unclear.

Exome sequencing, which allows study of the complete protein‐coding regions in the genome, is valuable in searching for underlying genetic variation in disease. Moreover, extensive exome sequencing studies from human tumors have indicated that there are a large number of mutations in each tumor [3](#feb412366-bib-0003){ref-type="ref"}. Accumulating evidence suggests that genetic change is specific for insulinomas, such as high loss of heterozygosity rates on chromosome 22q and gain of 9q34 [4](#feb412366-bib-0004){ref-type="ref"}, [5](#feb412366-bib-0005){ref-type="ref"}. Additionally, exome sequencing has revealed that there was a somatic mutation in the DNA‐binding zinc finger of the transcription factor Yin Yang 1 in insulinoma [6](#feb412366-bib-0006){ref-type="ref"}, [7](#feb412366-bib-0007){ref-type="ref"}, [8](#feb412366-bib-0008){ref-type="ref"}.

In order to further screen for potential genetic alterations in insulinoma, we selected the tumor tissue and matched blood of patients with insulinoma and performed exome sequencing and analysis of deleterious effects on the protein. In this study, we obtained a total of 55 gene mutations in insulinoma. Among them, mutations in *MEN1* were most related to the pathology of insulinoma, which provides evidence for use in early disease screening and target treatment of insulinoma.

Materials and methods {#feb412366-sec-0002}
=====================

Insulinoma patient samples {#feb412366-sec-0003}
--------------------------

In our present study, three patients (INS1, INS2 and INS3) with primary insulinoma were enrolled from the Second Hospital of Hebei Medical University. The paired tumor and a peripheral blood sample for DNA extraction were collected from the patients after surgical removal. The insulinoma was diagnosed depending on current clinical guidelines and histopathological confirmation [9](#feb412366-bib-0009){ref-type="ref"}. The diagnosis was established using the following six tight criteria: (a) documented blood glucose levels ≤ 2.2 mmol·L^−1^ (≤ 40 mg·dL^−1^); (b) concomitant insulin levels ≥ 66 μU·L^−1^ (≥ 36 pmol·L^−1^; ≥ 3 μU·L^−1^); (c) C‐peptide levels ≥ 200 pmol·L^−1^; (d) proinsulin levels ≥ 5 pmol·L^−1^; (e) β‐hydroxybutyrate levels ≤ 2.7 mmol·L^−1^; (f) absence of sulfonylurea (metabolites) in the plasma and/or urine. Written consent forms were obtained from the enrolled participants, and the research protocol was approved by the ethics committee of the Second Hospital of Hebei Medical University (2017‐R086) and complied with the principles of the Declaration of Helsinki. Clinical information for the patients is shown in Table [1](#feb412366-tbl-0001){ref-type="table-wrap"}.

###### 

Clinical information for the patients with insulinoma. INS1, INS2 and INS3 represent the three patients with insulinoma

  Sample   Gender   Age at diagnosis (years)   Grade   Metastatic disease   Tumor size (cm)   Ki67
  -------- -------- -------------------------- ------- -------------------- ----------------- ------
  INS1     Male     64                         G2      No                   0.6               2%
  INS2     Female   75                         G1      No                   0.8               2%
  INS3     Female   57                         G2      No                   1.0               2%
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Exome sequencing and data analysis {#feb412366-sec-0004}
----------------------------------

Genomic DNA was isolated from blood and tissue and was controlled for quality by measuring its concentration using a Nanodrop 2000 (Illumina, San Diego, CA, USA) and measuring fragmentation by agarose gel electrophoresis. Qualified Genomic DNA was prepared for exome sequencing with an Agilent SureSelect Human All Exon 50 Mb Exon Kit (Agilent Technologies, Santa Clara, CA, USA). The genomic DNA of each sample was fragmented and captured for exome sequencing with the Illumina HiSeq 2500 Sequencer platform (Illumina). For each sample, sequencing reads with 125‐bp paired‐end and *Q* ~30~ \> 92% were generated.

After filtering the low quality and contaminating reads, sequence reads were mapped to the human genome sequence (hg19) using the Burrows--Wheeler alignment tool (<http://bio-bwa.sourceforge.net/>), which generated the sequence alignment/map file. The PCR duplicate reads were further removed using the [picard]{.smallcaps} software program.

Single nucleotide variant detection and annotation {#feb412366-sec-0005}
--------------------------------------------------

To obtain the important candidate genes, the [mutect]{.smallcaps} software [10](#feb412366-bib-0010){ref-type="ref"} was used to detect single nucleotide variants (SNVs). Variants were filtered for minimum genotype quality of 50 and minimum coverage depths of 10. Then, the software [annovar]{.smallcaps} (<http://www.openbioinformatics.org/annovar/>) was applied to annotate the qualified variants. Finally, the variants were obtained and the deleteriousness of variants was subsequently predicted by various bioinformatics programs (e.g. [sift]{.smallcaps},[polyphen]{.smallcaps}2, [lrt]{.smallcaps},[mutationtaster]{.smallcaps},[mutationassessor]{.smallcaps},[fathmm]{.smallcaps},[radialsvm]{.smallcaps},[lr]{.smallcaps}).

Results {#feb412366-sec-0006}
=======

General characteristics of the patients {#feb412366-sec-0007}
---------------------------------------

We studied three patients with insulinoma, two female and one male. None had a family history of insulinoma. Moreover, we also excluded multiple endocrine neoplasia type 1 (MEN‐1 syndrome) from non‐tumor tissue. The WHO grading classification of pancreatic neuroendocrine tumors updated in 2010 includes neuroendocrine tumor G1, neuroendocrine tumor G2, neuroendocrine carcinoma G3 and mixed adenoneuroendocrine carcinoma [11](#feb412366-bib-0011){ref-type="ref"}. Depending on the classification system [12](#feb412366-bib-0012){ref-type="ref"}, two patients (INS1 and INS3) were classified as Grade II and one was classified as Grade I in this study. All presented with signs and symptoms of hypoglycemia. The hypoglycemia was corrected in all cases after surgical removal. General pathological and demographic characteristics for the three patients are shown in Table [1](#feb412366-tbl-0001){ref-type="table-wrap"}.

Genetic analysis {#feb412366-sec-0008}
----------------

Genomic DNA from insulinomas and matched blood samples was subjected to whole exome sequencing. After mapping of the human genome sequence (hg19), a total of \> 86% of the exome region was covered (Table [2](#feb412366-tbl-0002){ref-type="table-wrap"}). Exome sequencing analysis overall identified 40 210, 40 272 and 41 910 SNVs for tumor tissue, and 41 106, 40 050 and 41 451 SNVs for the matched blood samples. We identified 55 rare somatic mutations among the three patients, of which 39 were non‐synonymous, four were nonsense and 12 were synonymous. An overview of detected somatic mutations after exome sequencing is provided in Table [3](#feb412366-tbl-0003){ref-type="table-wrap"}. *MEN1* gene nonsense mutations occurred in two different tumor samples. A c. 681C\>G; p.Tyr227\* mutation was found in exon 4 of the *MEN1* gene in INS1, and c. 346G\>T; p.Glu116\* mutation was found in exon 2 of the *MEN1* gene in INS2. The mutations were not present in the corresponding leukocyte DNA. Additionally, these mutations were predicted to be damaging by [sift]{.smallcaps} or [lrt]{.smallcaps}.

###### 

Summary of sequencing data. C1, C2 and C3: tissues of three patients with insulinoma; N1, N2 and N3: blood of three patients with insulinoma

  Sample   Reads         Read length (bp)   \> *Q* ~30~ (%)   Exome size (bp)   Exome coverage
  -------- ------------- ------------------ ----------------- ----------------- ----------------
  C1       104 472 186   125                94.82             74 856 280        87.36%
  C2       107 751 402   125                92.34             74 856 280        87.79%
  C3       112 709 600   125                94.69             74 856 280        88.19%
  N1       110 592 066   125                94.5              74 856 280        87.90%
  N2       98 905 302    125                94.49             74 856 280        86.08%
  N3       109 660 740   125                94.58             74 856 280        88.44%
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###### 

Overview of the gene mutations found by exome sequencing in the three patients with insulinoma

  Sample   Chr   Start          Ref   Alt   Gene         Mutation type   AA change
  -------- ----- -------------- ----- ----- ------------ --------------- ---------------
  INS1     1     1.1 × 10^8^    G     A     *PSRC1*      Nonsynonymous   p.Ala227Val
  INS1     2     1 926 848      A     G     *MYT1L*      Synonymous      p.Asn231Asn
  INS1     2     2.38 × 10^8^   T     C     *COL6A3*     Nonsynonymous   p.Glu1565Gly
  INS1     3     1.47 × 10^8^   C     T     *ZIC4*       Nonsynonymous   p.Arg246His
  INS1     3     1.89 × 10^8^   C     T     *TPRG1*      Synonymous      p.Leu120Leu
  INS1     5     1.46 × 10^8^   G     T     *PPP2R2B*    Nonsynonymous   p.Pro235Thr
  INS1     6     32 548 632     T     A     *HLA‐DRB1*   Nonsynonymous   p.Arg218Ser
  INS1     7     1 542 657      G     A     *INTS1*      Nonsynonymous   p.Arg77Cys
  INS1     7     4 249 780      T     A     *SDK1*       Nonsense        p.Leu329\*
  INS1     7     1.48 × 10^8^   A     G     *CNTNAP2*    Nonsynonymous   p.Lys1156Glu
  INS1     7     1.57 × 10^8^   G     T     *PTPRN2*     Nonsynonymous   p.Ser827Tyr
  INS1     9     99 157 190     A     G     *ZNF367*     Synonymous      p.Cys202Cys
  INS1     10    99 153 502     C     A     *RRP12*      Nonsynonymous   p.Ala157 Ser
  INS1     10    1.3 × 10^8^    C     G     *MKI67*      Nonsynonymous   p.Gly477Ala
  INS1     11    64 575 141     G     C     *MEN1*       Nonsense        p.Tyr227\*
  INS1     11    1.02 × 10^8^   A     G     *CEP126*     Nonsynonymous   p.Ile674Val
  INS1     13    95 887 080     G     A     *ABCC4*      Synonymous      p.Ala105Ala
  INS1     14    74 968 287     G     T     *LTBP2*      Nonsynonymous   p.Pro1726Gln
  INS1     16    28 943 787     G     C     *CD19*       Nonsynonymous   p.Gly70Ala
  INS1     16    31 405 651     C     A     *ITGAD*      Nonsynonymous   p.Phe42Leu
  INS1     17    21 318 727     A     T     *KCNJ12*     Nonsynonymous   p.Met25Leu
  INS1     17    57 761 285     A     G     *CLTC*       Nonsynonymous   p.His1462Arg
  INS1     19    10 799 330     G     A     *ILF3*       Nonsynonymous   p.Gly843Ser
  INS2     1     22 332 008     T     C     *CELA3A*     Synonymous      p.Asp66Asp
  INS2     1     40 229 393     G     A     *BMP8B*      Synonymous      p.Leu313Leu
  INS2     6     32 007 839     G     T     *CYP21A2*    Nonsynonymous   p.Ala236Ser
  INS2     8     52 733 231     G     A     *PCMTD1*     Nonsense        p.Arg176\*
  INS2     8     88 298 821     T     A     *CNBD1*      Nonsynonymous   p.Tyr322Asn
  INS2     8     1.25 × 10^8^   G     A     *TMEM65*     Nonsynonymous   p.Ala179Val
  INS2     8     1.25 × 10^8^   T     C     *TMEM65*     Nonsynonymous   p.Tyr176Cys
  INS2     9     1.13 × 10^8^   C     A     *SVEP1*      Nonsynonymous   p.Arg902Leu
  INS2     11    64 577 236     C     A     *MEN1*       Nonsense        p.Glu116\*
  INS2     11    89 018 006     C     A     *TYR*        Nonsynonymous   p\. Pro417His
  INS2     12    6 787 522      G     A     *ZNF384*     Nonsynonymous   p.Pro153Ser
  INS2     12    9 243 947      A     G     *A2M*        Synonymous      p.Ser773Ser
  INS2     12    1.25 × 10^8^   A     G     *UBC*        Synonymous      p.Asp647Asp
  INS2     17    7 671 513      G     A     *DNAH2*      Nonsynonymous   p.Arg1290His
  INS2     17    7 834 438      C     G     *TRAPPC1*    Nonsynonymous   p\. Ser67Thr
  INS2     17    34 797 666     G     A     *TBC1D3B*    Synonymous      p.Ala490Ala
  INS2     19    41 355 849     A     G     *CYP2A6*     Synonymous      p\. Leu73Leu
  INS2     X     37 027 691     T     C     *FAM47C*     Nonsynonymous   p.Phe403Ser
  INS3     1     12 854 188     T     C     *PRAMEF1*    Nonsynonymous   p.Cys138Arg
  INS3     2     1.28 × 10^8^   G     A     *MYO7B*      Nonsynonymous   p.Gly163Asp
  INS3     4     1.52 × 10^8^   C     A     *RPS3A*      Nonsynonymous   p.Asn147Lys
  INS3     4     1.52 × 10^8^   A     C     *RPS3A*      Nonsynonymous   p.Gln157Pro
  INS3     5     1.4 × 10^8^    T     C     *PCDHA5*     Nonsynonymous   p.Val596Ala
  INS3     6     99 850 428     T     C     *PNISR*      Nonsynonymous   p.Lys439Glu
  INS3     6     1.38 × 10^8^   C     T     *OLIG3*      Nonsynonymous   p.Ala175Thr
  INS3     8     33 449 689     C     A     *DUSP26*     Nonsynonymous   p.Ala160Ser
  INS3     10    21 903 830     T     G     *MLLT10*     Nonsynonymous   p.Cys194Gly
  INS3     11    1 093 437      G     C     *MUC2*       Synonymous      p.Thr1752Thr
  INS3     11    1.26 × 10^8^   C     T     *PUS3*       Nonsynonymous   p.Glu143Lys
  INS3     16    7 629 904      C     T     *RBFOX1*     Synonymous      p.Asp152Asp
  INS3     17    79 667 512     G     A     *HGS*        Nonsynonymous   p.Ser633Asn
  INS3     19    19 030 142     G     A     *COPE*       Nonsynonymous   p.Pro6Ser
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Mutation of *MEN1* gene {#feb412366-sec-0009}
-----------------------

The p.Tyr227\* mutation (SWLYLKGSYMRCDRKMEV) and p.Glu116\* mutation (VSSRELVKKVSDVIWNSL) both resulted in a significant truncation of menin, which may destroy the functional domain and affect its function. Amino acids of p.Tyr227\* and p.Glu116\* mutations are highly conserved across multiple species (Fig. [1](#feb412366-fig-0001){ref-type="fig"}A,B). Moreover, two nonsense mutations locate in the functional domain of *MEN1*, indicating that it may affect the binding of lysine methyltransferase 2A (Fig. [1](#feb412366-fig-0001){ref-type="fig"}C). In the current study, the nonsense mutations happened early in the sequence of *MEN1*, which may obviously result in a non‐functional gene product (Fig. [1](#feb412366-fig-0001){ref-type="fig"}D).

![Nonsense mutation in *MEN1*. (A) Conservation of p.Tyr227\* in the MEN1 protein. (B) Conservation of p.Glu116\* in the MEN1 protein. (C) Locations of p.Tyr227\* and p.Glu116\* mutations in the conserved domain in the MEN1 protein. (D) Location of p.Tyr227\* and p.Glu116\* mutations on the crystal structure of the MEN1 protein.](FEB4-8-295-g001){#feb412366-fig-0001}

Discussion {#feb412366-sec-0010}
==========

Insulinoma is a common neuroendocrine tumor with an incidence of four in every 1 million persons annually [13](#feb412366-bib-0013){ref-type="ref"}. Moreover, most of the insulinomas arise sporadically. Although rare, it has the potential to produce profound metabolic derangements that require early recognition and treatment. In this study, exome sequencing was performed on three sporadic insulinoma cases to delineate genetic contributors to this rare endocrine tumor. Although the overall frequency of somatic mutations was low and predicted to be damaging, there were two nonsense variants that occurred in *MEN1* in two of the three patients, namely a c. 681C\>G; p.Tyr227\* mutation in exon 4 of *MEN1* and a c. 346G\>T; p.Glu116\* mutation in exon 2 of *MEN1*. Our result showed that the mutations in *MEN1* may play an important role in the development of insulinoma. However, further functional research is needed to validate their roles.

*MEN1* consists of 10 exons [9](#feb412366-bib-0009){ref-type="ref"} and encodes a protein with 615 amino acids [14](#feb412366-bib-0014){ref-type="ref"}; it is considered a putative tumor suppressor gene associated with neuroendocrine tumors [15](#feb412366-bib-0015){ref-type="ref"}. Menin, the encoded protein of *MEN1*, is a typical GTPase stimulated by nm23. It is mostly found in the nucleus and can regulate gene expression in a positive or negative way, and it has been demonstrated to interact with transcription activators, transcription repressors, cell signaling proteins and various other proteins. In addition, it plays major roles in DNA repair, cell cycle regulation and chromatin remodeling. Generally, menin is considered as a transcriptional regulator and interacts with a number of nuclear and cytosolic proteins, which indicates that it may participate in various biological pathways of tumor formation [16](#feb412366-bib-0016){ref-type="ref"}, [17](#feb412366-bib-0017){ref-type="ref"}, [18](#feb412366-bib-0018){ref-type="ref"}. Additionally, a number of sporadic endocrine tumors, including parathyroid adenomas, pancreatic insulinomas and pituitary prolactinomas, have somatic mutations of *MEN1* alleles, suggesting that *MEN1* may play a role in non‐hereditary endocrine tumors [15](#feb412366-bib-0015){ref-type="ref"}, [19](#feb412366-bib-0019){ref-type="ref"}, [20](#feb412366-bib-0020){ref-type="ref"}. Our results showed that *MEN1* mutations were found in two of the three insulinoma patients, which provided further evidence that *MEN1* might be an important factor in the pathological process of insulinoma.

It is noted that insulinomas can occur sporadically or in combination with MEN‐1 syndrome. Moreover, the *MEN1* gene is the first gene that has been identified as a candidate gene in the tumorigenesis of insulinoma. MEN‐1 syndrome represents an autosomal dominant disorder related to mutations in the *MEN1* gene mapped to chromosome 11q13 [21](#feb412366-bib-0021){ref-type="ref"}, [22](#feb412366-bib-0022){ref-type="ref"}. Generally, simple and local tumor enucleation of MEN‐1 syndrome‐associated insulinomas is not likely to be curative. Although genetic testing for *MEN1* fails to detect mutation rate of 10--25%, it plays a vital role in identifying patients with hereditary insulinomas [23](#feb412366-bib-0023){ref-type="ref"}, [24](#feb412366-bib-0024){ref-type="ref"}. Therefore, genetic testing for MEN‐1 syndrome is beneficial to clinical diagnosis. Okamoto *et al*. [25](#feb412366-bib-0025){ref-type="ref"} suggested that a novel six‐nucleotide insertion in exon 4 of the *MEN1* gene might contribute to the familial insulinoma. A prior study indicated that *MEN1* gene mutations were lacking in 27 sporadic insulinomas [26](#feb412366-bib-0026){ref-type="ref"}. By evaluating a large family with malignant insulinoma and hyperparathyroidism, Hasani‐Ranjbar *et al*. [27](#feb412366-bib-0027){ref-type="ref"} found a novel *MEN1* gene frameshift germline mutation, which was associated with malignant insulinoma. Moreover, a recent study found several novel pathogenic *MEN1* mutations in sporadic cases of insulinoma [28](#feb412366-bib-0028){ref-type="ref"}. Herein, we found mutations in *MEN1* on chromosome 11 in patients with insulinoma, which had a damaging role in the function of the encoded protein. Our finding was consistent with other studies indicating the role of *MEN1* mutation in human sporadic insulinomas [26](#feb412366-bib-0026){ref-type="ref"}, [29](#feb412366-bib-0029){ref-type="ref"}, [30](#feb412366-bib-0030){ref-type="ref"}, [31](#feb412366-bib-0031){ref-type="ref"}, [32](#feb412366-bib-0032){ref-type="ref"}, which provided a crucial clue in the treatment of insulinoma. Interestingly, Waldmann *et al*. [33](#feb412366-bib-0033){ref-type="ref"} found the p.E116X mutation in exon 2 of the *MEN1* gene in 21 patients with MEN‐1 syndrome and adrenal lesions. In addition, Turner *et al*. [34](#feb412366-bib-0034){ref-type="ref"} identified the p.Y227X mutation in exon 4 of the *MEN1* gene in multiple endocrine neoplasia type 1. This further suggested that *MEN1* was significantly associated with insulinoma.

Conclusions {#feb412366-sec-0011}
===========

In the current study, exome sequencing for three sporadic insulinomas identified two somatic nonsense mutations in *MEN1* (c. 681C\>G; p.Tyr227\* and c. 346G\>T; p.Glu116\*), which might induce a non‐functional gene product and contribute to the oncogenesis of sporadic insulinoma. However, there were some limitations in this study. The samples selected were small and larger samples are further needed to validate their roles in insulinoma. Further studies are needed to precisely explore the role of genetic mutations of *MEN1* in clinical manifestations of these patients. In addition, validation of *MEN1* mutations (such as by Sanger sequencing) and study of the underlying biological function of the *MEN1* mutations is needed in a further study.
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